According to a research report published earlier today, Canaccord has increased Nu Skin Enterprises' NUS PT from $57 to $66.
In the report, Canaccord said, "Our thesis remains that Nu Skin is in the midst of a powerful product cycle, coupled with a concerted effort to improve margins that should drive above-average EPS growth. Nu Skin reported a good Q1 with much stronger sales, slightly higher earnings and clear indications of building momentum on the latest round of product launches."
Canaccord maintains its Buy rating on Nu Skin, which is currently trading at $54.75.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in